About Beyondmedicine
Building the evidence base for digital TMD care
We are a team of clinicians, engineers, and regulatory specialists building a prescription digital therapeutic that clinicians can trust and rely on.
Mission
To give every TMD patient access to evidence-based treatment, and every clinician the tools to prescribe and monitor it with confidence.
Vision
A future where digital therapeutics are a standard part of dental and orofacial care, backed by the same rigor as any other prescribed treatment.
Technology
A clinical-grade software platform
Clickless is built on a foundation of behavioral science, structured exercise programming, and clinician-facing data infrastructure.
The platform pairs a patient-facing mobile app with a clinician dashboard, connected through a secure data layer that supports prescription workflows, adherence tracking, and patient-reported outcome collection. Read more on the Technology page.
Leadership
Physician-founded. Mission-driven.
All three founders are licensed dentists working on Beyondmedicine.
Kim Dae-hyun
CEO · Founder
Former CSO of a COVID-19 AI diagnostic platform. Previously founded five ventures spanning brands and platforms.
Park Sang-yoon
CRO · Founder
DDS, Seoul National University Dental Hospital. Professor of Oral & Maxillofacial Surgery, Hallym University Hospital.
Kim Young-kyun
CMO · Founder
Professor of Oral & Maxillofacial Surgery, Seoul National University Bundang Hospital. Recognized by Expertscape as Korea's top TMD expert.
Timeline
Company milestones
2021
Company founded
Beyondmedicine was founded to bring evidence-based digital therapeutics to TMD care.
2022
Clickless prototype developed
The first version of the Clickless patient app and clinician dashboard was built with clinical advisors.
2023
Clinical trial initiated
A multi-center randomized controlled trial began in partnership with university dental hospitals.
2024
Korea regulatory filing
Beyondmedicine submitted Clickless for review as a digital therapeutic medical device in Korea.
2025
FDA De Novo preparation
Beyondmedicine began preparing its submission strategy for the FDA De Novo pathway.
2026 and beyond
Global expansion
Plans for CE marking in Europe and PMDA review in Japan, alongside continued clinical publication.